<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968006</url>
  </required_header>
  <id_info>
    <org_study_id>Sita-EPC</org_study_id>
    <nct_id>NCT00968006</nct_id>
  </id_info>
  <brief_title>Effect of Sitagliptin on Endothelial Progenitor Cells</brief_title>
  <official_title>Effects of 4-week Sitagliptin Therapy on Endothelial Progenitor Cells in Type 2 Diabetic Patients. A Non-randomized Controlled Open-label Pilot Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelial progenitor cells (EPCs) are involved in cardiovascular homeostasis, through&#xD;
      angiogenesis and endothelial healing. Diabetic patients have a high risk of cardiovascular&#xD;
      events and low levels of circulating EPCs.&#xD;
&#xD;
      Sitagliptin is an oral DPP-IV antagonist, approved for the treatment of type 2 diabetes. It&#xD;
      increases the bioavailability of endogenous incretins, thus improving insulin and glucagon&#xD;
      secretion. SDF-1, one of the major EPC regulators, is also a substrate of DPP-IV. This study&#xD;
      tests the hypothesis that sitagliptin increases the levels of circulating EPCs in type 2&#xD;
      diabetic patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic patients suffer an elevated wirk of cardiovascular events, which strongly impact on&#xD;
      morbidity and mortality. The mechanisms that lead to cardiovascular disease in diabetes&#xD;
      include alterations in the endothelial layer, due to hyperglycemia, oxidative stress and&#xD;
      other associated abnormalities. Endothelial progenitor cells (EPCs) are bone marrow-derived&#xD;
      cells involved in endothelial repair after injury, and they have been found to be reduced in&#xD;
      diabetic patients. Thus, reduced EPCs in diabetes may be another mechanism of vascular&#xD;
      disease induction. Reduction of EPCs in diabetes is attributable at least in part to the&#xD;
      impairment of bone marrow mobilization, which is regulated by the chemokine SDF-1alpha, among&#xD;
      others.&#xD;
&#xD;
      The oral hypoglycemia agent sitagliptin is a dipeptidyl dipeptidase-IV inhibitor, which&#xD;
      prevents degradation of endogenous incretins (GIP and GLP-1), thus re-equilibrating insulin&#xD;
      and glucagon secretion. Sitagliptin may also increase the concentrations of SDF-1alpha, which&#xD;
      is another substrate of DPP-IV. The hypothesis is that sitagliptin may increase circulating&#xD;
      EPC levels, through SDF-alpha.&#xD;
&#xD;
      This is going to be a pilot, non-randomized controlled 4-week trial of 100 mg oral&#xD;
      sitagliptin therapy added to metformin/sulphonylureas in poorly controlled type 2 diabetic&#xD;
      patients. At baseline and 4 weeks after the initiation of therapy blood samples will be drawn&#xD;
      for the determination of circulating EPC levels, and concentrations of SDF-1alpha. EPCs will&#xD;
      be defined as CD34+KDR+ cells and measured by flow cytometry as previously described in&#xD;
      detail. SDF-1alpha will be measured using ELISA kits according to the manufacturer's&#xD;
      instructions.&#xD;
&#xD;
      Changes between baseline and 4 weeks will be evaluated using two-tailed paired Student's t&#xD;
      test and statistical significance accepted at p&lt;0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in circulating CD34+KDR+ endothelial progenitor cells</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SDF-1alpha concentrations</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100 mg once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No change in anti-diabetic treatment regimen for at least 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100 mg once daily for 4 weeks</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Januvia; Xelevia; Tesavel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes;&#xD;
&#xD;
          -  Both genders&#xD;
&#xD;
          -  Age 40-80&#xD;
&#xD;
          -  fasting c-peptide &gt;=1.0 ng/L&#xD;
&#xD;
          -  Therapy with metformin or sulphonylureas&#xD;
&#xD;
          -  HbA1c &gt;7.0%&#xD;
&#xD;
          -  No contraindications to sitagliptin use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Age &lt;40 or &gt;80&#xD;
&#xD;
          -  fasting c-peptide &lt;1.0 ng/L&#xD;
&#xD;
          -  Therapy with TZD&#xD;
&#xD;
          -  HbA1c &lt;=7.0%&#xD;
&#xD;
          -  Acute concomitant diseases&#xD;
&#xD;
          -  Immunological disorders&#xD;
&#xD;
          -  Recent (within 3 months) cardiovascular events or surgery&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo Avogaro, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Clinical and Experimental Medicine, University of Padova, Medical School, Padova (Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Padova, Medical School</name>
      <address>
        <city>Padova</city>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010 Jul;33(7):1607-9. doi: 10.2337/dc10-0187. Epub 2010 Mar 31.</citation>
    <PMID>20357375</PMID>
  </results_reference>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <last_update_submitted>April 2, 2010</last_update_submitted>
  <last_update_submitted_qc>April 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Angelo Avogaro, Associate Professor (PI)</name_title>
    <organization>Dept Clinical and Experimental Medicine, University of Padova Medical School</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>endothelium</keyword>
  <keyword>stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

